STUDY OF THE EFFECTIVENESS OF THE USE OF MOXONIDINE IN WOMEN WITH ARTERIAL HYPERTENSION AND MENOPAUSEAL METABOLIC SYNDROME
DOI:
https://doi.org/10.32782/health-2023.4.11Keywords:
hypertension, moxonidine, target blood pressure level, menopausal metabolic syndrome, lipid spectrum, blood pressureAbstract
The article presents the results of a clinical trial to study the efficacy of moxonidine as part of complex antihypertensive therapy for stage 2 (grade 2–3) hypertension in women with menopausal metabolic syndrome (MMS), compared with basic complex antihypertensive therapy to achieve the target level of blood pressure (BP). The mechanisms of antihypertensive action of moxonidine as part of complex antihypertensive therapy were considered. Patients in the main (16 women) and control groups (16 women) received basic antihypertensive therapy (triplixam in a dose of 10/2.5/10) on an inpatient and outpatient basis. In addition, patients in the main group took a second-generation centrally acting drug, moxonidine, at a dose of 0.4 mg per day to achieve the target blood pressure level. The study was conducted before and 3 months after starting this combination. The criterion for the effectiveness of moxonidine as part of complex therapy was the achievement of the target blood pressure level. According to the results obtained, moxonidine as part of complex antihypertensive therapy contributed to the achievement of the target level of blood pressure in 87.9% of women in the main group. After 3 months of treatment, the reduction in systolic blood pressure was 30 mm Hg, diastolic blood pressure – 24.9 mm Hg. It has been proved that the degree of blood pressure (BP) reduction under the influence of the combination of Moxonidine/Triplixam provides a significant hypotensive effect in patients with metabolic syndrome in menopause with severe hypertension. In addition, moxonidine reduced the variability of systolic blood pressure during the day. The antihypertensive effect of moxonidine was realized against the background of improved lipid and carbohydrate metabolism. The study showed that moxonidine reduced heart rate in patients with sympathetic nervous system hyperactivity, positively affecting blood pressure levels throughout the day. The study evaluated the safety of moxonidine in combination with basic therapy.
References
Williams B., Mancia G., Spiering W. et al. ESC Scientific Document Group (2018) ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018. № 39(33). Р. 3021–3104.
Nanchahal К., Ashton W.D, Wood D.A. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women. J. Hypertens. 2020. № 18. Р. 833–841.
Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab.2003. № 88. Р. 2404–2411.
Ernsberger P. Pharmacology of moxonidine: аn I1-imidazoline receptor antagonist. J Cardiovasc. Pharmacol. 2000. № 35(7). Suppl. 4, S. 27–41.
Derosa G., Cicero A.F., D’Angelo A. et al. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Clin. Ther. 2007. № 29(4). Р. 602–610.
Fahed G., Aoun L., Zerdan М.В., Allam S., Bouferraa Y., Assi H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2007. № 23(2). Р. 786–792. DOI: 10.3390/ijms23020786/.
Rochlani Y., Pothineni N.V., Kovelamudi S., Mehta J.L. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017. № 11(8). Р. 215–225. DOI: 10.1177/1753944717711379.
